A share price of Iovance Biotherapeutics Inc [IOVA] is currently trading at $10.67, up 1.04%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IOVA shares have gain 4.20% over the last week, with a monthly amount glided 15.35%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Iovance Biotherapeutics Inc [NASDAQ: IOVA] stock has seen the most recent analyst activity on October 24, 2024, when UBS initiated its Buy rating and assigned the stock a price target of $17. Previously, Piper Sandler downgraded its rating to Neutral on July 29, 2024, and dropped its price target to $10. On November 20, 2023, Goldman initiated with a Buy rating and assigned a price target of $12 on the stock. Barclays reiterated its Overweight rating and decreased its price target to $18 on September 18, 2023. Wells Fargo upgraded its rating to a Overweight and raised its price target to $17 on May 30, 2023. In a note dated January 27, 2023, Piper Sandler upgraded an Overweight rating on this stock and boosted its target price from $11 to $14.
Iovance Biotherapeutics Inc experienced fluctuations in its stock price throughout the past year between $3.47 and $18.33. Currently, Wall Street analysts expect the stock to reach $21 within the next 12 months. Iovance Biotherapeutics Inc [NASDAQ: IOVA] shares were valued at $10.67 at the most recent close of the market. An investor can expect a potential return of 96.81% based on the average IOVA price forecast.
Analyzing the IOVA fundamentals
Trailing Twelve Months sales for Iovance Biotherapeutics Inc [NASDAQ:IOVA] were 32.77M which represents 12969.75% growth. Gross Profit Margin for this corporation currently stands at -1.07% with Operating Profit Margin at -14.01%, Pretax Profit Margin comes in at -13.61%, and Net Profit Margin reading is -13.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.65 and Total Capital is -0.53. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.43 points at the first support level, and at 10.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.02, and for the 2nd resistance point, it is at 11.38.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Iovance Biotherapeutics Inc [NASDAQ:IOVA] is 5.15. As well, the Quick Ratio is 4.85, while the Cash Ratio is 2.44. Considering the valuation of this stock, the price to sales ratio is 98.82, the price to book ratio is 4.13.
Transactions by insiders
Recent insider trading involved MCPEAK MERRILL A, Director, that happened on Feb 20 ’24 when 0.25 million shares were purchased. Director, Dukes Iain D. completed a deal on Feb 20 ’24 to buy 32000.0 shares. Meanwhile, Director Rothbaum Wayne P. bought 5.0 million shares on Feb 20 ’24.
